Latest Biotech News

The Centers for Medicare & Medicaid Services proposed two mandatory Medicare payment models designed to lower prices for branded drugs by benchmarking costs to prices paid in comparable countries....

The FDA approved Novo Nordisk’s oral semaglutide formulation, marking the first pill version of Wegovy authorized for chronic weight management and cardiovascular risk reduction. The decision...

CMS proposed two mandatory Medicare demonstration programs intended to tie Medicare drug prices to international benchmarks, a policy derived from the administration’s most-favored-nation (MFN)...

Boehringer Ingelheim struck an agreement with the U.S. administration to join a government-run purchasing platform and pledged up to $10 billion in U.S. investments through 2028 to expand...

AstraZeneca paid $100 million up front to secure ex‑China rights to Jacobio Pharmaceuticals’ phase I pan‑KRAS inhibitor, in a deal worth up to roughly $1.9 billion in milestones. The agreement...

Aktis Oncology filed for an IPO to raise capital for its miniprotein radiopharmaceutical pipeline, aiming to fund ongoing US phase 1b trials and further target expansion. The company highlighted...

Pfizer disclosed the death of a participant in a long‑term extension trial of Hympavzi (marstacimab), reporting a cerebellar infarction followed by cerebral hemorrhage. The company communicated...

Daiichi Sankyo voluntarily placed a partial recruitment and enrollment hold on the phase III IDeate‑Lung02 study of the antibody‑drug conjugate ifinatamab deruxtecan following a...

Shionogi agreed to acquire global rights to edaravone from Tanabe Pharma for $2.5 billion, securing an approved amyotrophic lateral sclerosis (ALS) therapy marketed in the U.S. as Radicava (oral...

Minimal residual disease (MRD) testing saw multiple high‑profile trial readouts and commercial consolidations in 2025, with the Phase III IMvigor011 trial using Natera’s Signatera test presenting...

The U.S. Food and Drug Administration approved Novo Nordisk’s oral formulation of semaglutide, branded as the Wegovy pill, for chronic weight management and cardiovascular risk reduction. The...

AstraZeneca agreed to acquire ex‑China rights to Jacobio Pharmaceuticals’ phase I pan‑KRAS inhibitor JAB‑23E73 in a deal worth up to $1.915 billion, with an immediate $100 million up‑front...

Boehringer Ingelheim struck an agreement with the U.S. administration to join the TrumpRx.gov direct‑purchase platform and pledged $10 billion of investment into U.S. research, development and...

Shionogi & Co. will acquire global rights to edaravone, an FDA‑approved therapy for amyotrophic lateral sclerosis (marketed as Radicava ORS and I.V. Radicava in the U.S.), under a $2.5 billion...

Federal prosecutors unsealed charges against six individuals alleging insider trading and stock manipulation that targeted biopharma companies and generated roughly $41 million in illicit gains....

Samsung Biologics’ U.S. subsidiary signed a definitive agreement to acquire Human Genome Sciences’ Rockville, Maryland manufacturing site from GSK for $280 million, marking Samsung’s first U.S....

Japan’s regulators approved Guardant Health’s Guardant360 companion diagnostic to detect ESR1 mutations and guide use of Eli Lilly’s Inluriyo in breast cancer patients. The Japanese clearance...

Harbour Biomed announced a collaboration with Bristol Myers Squibb to develop multispecific antibodies, receiving about $90 million up front and potential milestones that could exceed $1 billion....

Aktis Oncology filed for an initial public offering to raise capital for clinical development of its miniprotein radiopharmaceuticals, following partnerships and investments from Eli Lilly,...

Multiple late‑stage readouts in 2025 strengthened the commercial and clinical case for minimal residual disease (MRD) testing; the Phase III IMvigor011 trial used Natera’s tumor‑informed Signatera...